Use of Immunosuppressants and Biologicals in Patients with Previous Cancer
Author:
- Laurent BeaugerieLBLaurent Beaugerie
- 1 September 2013
- journal article
- review article
- Published by S. Karger AG in Digestive Diseases
- Vol. 31 (2) , 254-259
Abstract
Thiopurines promote Epstein-Barr virus-related lymphomas, nonmelanoma skin cancers and acute myeloid leukemias. Anti-tumor necrosis factor (anti-TNF) agents may inhibit or activate carcinogenesis according to the cellular pathways that are activated. A mild increase in the risk of melanoma has been reported in patients exposed to anti-TNF agents. Transplanted patients with previous history of cancer are at high risk of cancer recurrence when receiving posttransplant immunosuppressive therapy, particularly within the first 2 years of treatment. Few data exist for patients with chronic inflammatory disease. In the CESAME cohort that included essentially patients receiving thiopurines, there was no excess incidence of recurrent or new cancer associated with exposure to immunosuppressive therapy in the patients with previous cancer at cohort entry. In clinical practice, the decision to start or resume immunosuppressive therapy in inflammatory bowel disease (IBD) patients with recent cancer should be discussed case by case with cancer specialists. However, taken into account the experience of transplant specialists, it could be suggested not to consider a waiting period for women with adequately treated uterine high-grade cervical dysplasia. For invasive cancers, a waiting period of 2 years should be considered if possible. During this period, treatment of IBD should be restricted to 5-aminosalicylic acid, steroids, nutritional therapy, or surgery, except in case of aggressive IBD that cannot be controlled by these methods. A longer waiting period of 5 years could be recommended for the most aggressive forms of cancers, such as melanomas, aggressive breast cancers, sarcomas, urinary tract cancers, and myelomas.Keywords
This publication has 25 references indexed in Scilit:
- Treating rheumatic patients with a malignancyArthritis Research & Therapy, 2011
- Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics registerArthritis Care & Research, 2010
- Immunity, Inflammation, and CancerCell, 2010
- Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBITArthritis Research & Therapy, 2010
- Immune escape by Epstein–Barr virus associated malignanciesSeminars in Cancer Biology, 2008
- Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case–control studyBritish Journal of Cancer, 2008
- Azathioprine treatment photosensitizes human skin to ultraviolet A radiationBritish Journal of Dermatology, 2008
- Immunosuppressive Therapy and Malignancy in Organ Transplant RecipientsDrugs, 2007
- Cancer despite immunosurveillance: immunoselection and immunosubversionNature Reviews Immunology, 2006
- Classifying local disease recurrences after breast conservation therapy based on location and histologyCancer, 2002